Plymouth Meeting, PA – April 23, 2018: CRF Health, the leading provider of patient-centered eSource for the life sciences industry, today announced that its TrialMax Touch® and TrialMax Slate® solutions have been selected by a Global Category Japanese Pharmaceutical company for a significant pain trial. The Phase III trial will involve 800 screened and 320 randomized subjects across 40 sites in the US.
CRF Health’s TrialMax Touch® delivers an easy-to-use smartphone solution to collect the primary endpoint data of the study via a daily diary. With home-based patients and daily diary entries, the high compliance afforded by electronic data capture vs. paper was a key requirement. The high-quality solution was selected by the sponsor for the benefits it brings, such as streamlining data collection through instant capture, rather than requiring patients to visit a site, and a high compliance rate which is achieved through the solutions’ notification reminders, intuitive interface and mobility.
For the investigators in the study, TrialMax Slate® will provide the ability to send reminders to keep patients engaged, while the dashboard clearly displays the questionnaire status of all patient visits. This reduces site burden and increases the efficiency of the eCOA collection process by highlighting required and incomplete questionnaires.
“In the area of pain therapy there are a lot of questionnaires completed by the patient at home and these are typically critical endpoints to the study,” commented Rachael Wyllie, CRF Health’s CEO. “With our proven track record and unparalleled eCOA expertise, CRF Health was selected as the best provider to ease patient and site burden and maximize the capture of critical data.”
For further information on CRF Health and the TrialMax eCOA solutions, please visit www.crfhealth.com.
About CRF Health
CRF Health is the leading provider of patient-centered eSource for the life sciences industry. With experience in more than 800 clinical trials, over 100 languages and across 74 countries, CRF Health’s TrialMax® platform consistently demonstrates the industry’s highest data accuracy, patient and site compliance, and patient retention. The integrated TrialMax platform includes eCOA solutions for collecting PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes), ClinROs (Clinician or Rater Reported Outcomes), and PerfOs (Performance Outcomes), and features TrialConsent®, an electronic solution for collecting and managing informed consent in clinical trials. CRF Health’s eSource solutions improve trial engagement by making the patient the center of the clinical trial process.
Contact: media@crfhealth.com, +1 267.498.2350
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.